
Opinion|Videos|July 16, 2024
Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.
Advertisement
- In addition to cost, what factors influence coverage decisions for AD treatments?
- How do step-therapy protocols and prior authorization approval process influence the prescribing patterns of topical therapies (and progressing to systemic therapies) for AD among healthcare providers?
- What strategies can healthcare providers implement to streamline the PA approval process for topical AD therapies and reduce administrative burdens while still ensuring cost-effective care?
- Please discuss the burden providers face in terms of workload perspective, staffing constraints, etc, and what this means for patients
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5